Analyst Price Targets — CNTA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 20, 2026 9:12 am | — | Wells Fargo | $42.00 | $39.66 | TheFly | Centessa downgraded to Equal Weight from Overweight at Wells Fargo |
| February 23, 2026 9:07 pm | — | Wolfe Research | $40.00 | $25.49 | TheFly | Centessa initiated with an Outperform at Wolfe Research |
| January 29, 2026 2:25 pm | — | Truist Financial | $38.00 | $24.73 | TheFly | Centessa price target raised to $38 from $33 at Truist |
| January 8, 2026 12:54 pm | Danielle Brill | Truist Financial | $33.00 | $22.69 | TheFly | Centessa price target raised to $33 from $30 at Truist |
| January 5, 2026 12:24 pm | — | Needham | $38.00 | $23.69 | TheFly | Centessa price target raised to $38 from $35 at Needham |
| December 1, 2025 11:57 am | Mayank Mamtani | B.Riley Financial | $42.00 | $28.72 | StreetInsider | Centessa Pharmaceuticals (CNTA) PT Raised to $42 at B.Riley |
| November 5, 2025 1:03 pm | Danielle Brill | Truist Financial | $30.00 | $19.15 | StreetInsider | Truist Securities Comments on Centessa Pharmaceuticals (CNTA) Amid 18pct Drop |
| October 28, 2025 7:55 am | Sudan Loganathan | Stephens | $35.00 | $24.46 | StreetInsider | Stephens Starts Centessa Pharmaceuticals (CNTA) at Overweight |
| September 2, 2025 8:43 pm | — | Wells Fargo | $31.00 | $17.27 | TheFly | Centessa initiated with an Overweight at Wells Fargo |
| May 8, 2025 2:42 pm | Rudy Li | Chardan Capital | $30.00 | $12.41 | Benzinga | This Centessa Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Thursday |
Latest News for CNTA
BOSTON and LONDON, June 22, 2026 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage company developing a new class of medicines for the treatment of excessive daytime sleepiness and other neurological conditions, which entered into a definitive agreement on March 31, 2026 relating to its proposed acquisition by Eli Lilly and Company (“Lilly”), through a wholly owned subsidiary, today…
Proven Chief Medical Officer at several publicly listed and clinical-stage oncology companies with successful track record developing multiple modalities including radiotherapies from preclinical through global approvals across hematologic malignancies and solid tumors Played a leading role in clinical development and worldwide approvals of Erbitux® at Merck KGaA leading to its blockbuster status Led clinical…
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Centessa Pharmaceuticals plc (NasdaqGS: CNTA) to Eli Lilly and Company (NYSE: LLY). Under the terms of the proposed transaction, shareholders of Centessa will receive $38.00 in cash per share plus one non-transferrable…
B. Metzler seel. Sohn and Co. AG purchased a new position in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ: CNTA) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 38,432 shares of the company's stock, valued at approximately $961,000. A number of other large investors
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CNTA.
U.S. House Trading
No House trades found for CNTA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.